OmniAb (OABI) Total Current Liabilities (2021 - 2026)
OmniAb (OABI) reported Total Current Liabilities of $13.6 million for Q1 2026, up 18.93% year-over-year from $11.4 million in Q1 2025, and down 16.54% on a QoQ basis from $16.3 million in Q4 2025.
OmniAb (OABI) has 6 years of Total Current Liabilities data on file, last reported at $13.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 18.93% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (up 18.93% YoY) and the FY2025 annual result came in at $16.3 million, up 7.73% from the prior year.
- Total Current Liabilities fell to $13.6 million in Q1 2026 per OABI's latest filing, from $16.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $26.0 million in Q4 2022 and bottomed at $5.5 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $14.4 million (2024), against an average of $15.9 million.
- The widest annual swing landed in 2022, when Total Current Liabilities surged 10598.67%; it then sank 42.53% in 2024.
- Tracing OABI's Total Current Liabilities over 5 years: stood at $26.0 million in 2022, then slipped by 11.17% to $23.1 million in 2023, then tumbled by 34.73% to $15.1 million in 2024, then grew by 7.73% to $16.3 million in 2025, then decreased by 16.54% to $13.6 million in 2026.
- Per Business Quant, the three latest OABI Total Current Liabilities figures stand at $13.6 million (Q1 2026), $16.3 million (Q4 2025), and $13.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 13.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.57 Mn |
| Dec 31, 2025 | 16.25 Mn |
| Sep 30, 2025 | 13.28 Mn |
| Jun 30, 2025 | 12.64 Mn |
| Mar 31, 2025 | 11.41 Mn |
| Dec 31, 2024 | 15.09 Mn |
| Sep 30, 2024 | 14.40 Mn |
| Jun 30, 2024 | 14.15 Mn |
| Mar 31, 2024 | 17.52 Mn |
| Dec 31, 2023 | 23.12 Mn |
| Sep 30, 2023 | 25.06 Mn |
| Jun 30, 2023 | 24.24 Mn |
| Mar 31, 2023 | 21.68 Mn |
| Dec 31, 2022 | 26.02 Mn |
| Sep 30, 2022 | 10.27 Mn |
| Jun 30, 2022 | 6.98 Mn |
| Mar 31, 2022 | 5.46 Mn |
| Dec 31, 2021 | 20.58 Mn |
| Sep 30, 2021 | 95,969.00 |